Vitamin D3 and analogues modulate the expression of CSF-1 and its receptor in human dendritic cells

Kejian Zhu,Regine Gläser,Ulrich Mrowietz
DOI: https://doi.org/10.1016/S0006-291X(02)02357-4
IF: 3.1
2002-01-01
Biochemical and Biophysical Research Communications
Abstract:The active vitamin D3-metabolite 1,25(OH)2D3 inhibits the interleukin 4/granulocyte–macrophage colony-stimulating factor (IL-4/GM-CSF)-induced differentiation of human monocytes into dendritic cells without altering survival. Colony-stimulating factor 1 (CSF-1) is an important survival factor for cells of the monocytic lineage. We therefore investigated whether the inhibitory activity of 1,25(OH)2D3 is paralleled by a regulation of CSF-1 and its receptor. Purified human monocytes were cultured together with IL-4/GM-CSF in the presence of 1,25(OH)2D3, its analogue tacalcitol, the low-affinity vitamin D receptor ligand 24,25(OH)2D3, or the solvent ethanol for up to 5 days. Expression of CSF-1, CSF-1R, and GM-CSF mRNA was measured by RT-PCR. Protein secretion for CSF-1 was measured by ELISA, expression of CSF-1R by flow cytometry. The results showed that 1,25(OH)2D3 and tacalcitol significantly up-regulated CSF-1 mRNA-expression and protein secretion in a dose-dependent manner. The effect of 1,25(OH)2D3 occurred already after 1h of pre-treatment. In contrast, CSF-1R mRNA- and cell surface-expression was down-regulated simultaneously. The solvent ethanol and 24,25(OH)2D3 were without effect. GM-CSF mRNA expression was not modulated in 1,25(OH)2D3-treated cells. These data point towards a distinct and specific regulation of CSF-1 and its receptor by 1,25(OH)2D3 and its analogue tacalcitol in human monocytes which parallels the inhibition of differentiation into dendritic cells without altering survival.
What problem does this paper attempt to address?